Jupiter Life Line Hospitals Ltd. (JLHL) AI Stock Analysis

Jupiter Life Line Hospitals Ltd.

(NSE:JLHL)

Select Model

Rating:59Neutral

Price Target:INR 255.00▼(-3.26% Downside)

Action:reiterated

Date:10/26/26

The score is led by improved fundamentals (growth, sustained profitability, and a stronger balance sheet) and a generally constructive earnings call around execution and expansion. This is tempered by materially negative recent free cash flow and a weak technical setup (below key moving averages with negative MACD). Valuation is also demanding (high P/E with a very low dividend yield), limiting upside unless execution remains strong.

Positive Factors

Sustained revenue growth and profitabilityConsistent revenue expansion alongside a shift from losses to sustained profitability indicates that the hospital network is gaining operating scale. This strengthens internal funding capacity and provides a more durable earnings base as existing facilities mature and newer hospitals ramp.

Negative Factors

Weak free cash flow after reinvestmentPositive operating cash flow is being outweighed by capital spending and/or working-capital absorption, leaving cash generation after reinvestment weak. Persistent negative free cash flow could increase reliance on debt or constrain the pace and flexibility of future expansion.

Jupiter Life Line Hospitals Ltd. (JLHL) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 84.88B
Dividend Yield: 0.08%
Average Volume (3M): 94.73K
Price to Earnings (P/E): 45.3
Beta (1Y): 0.23
Revenue Growth: 16.71%
EPS Growth: -6.09%
Country: India
Employees: 3,002
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Jupiter Life Line Hospitals Ltd. Business Overview & Revenue Model

Company Description

Jupiter Life Line Hospitals Limited, established in Mumbai, India, in 2002, operates as a multi-specialty healthcare provider throughout the country under its Jupiter brand. The company delivers a comprehensive range of medical and surgical services...

Jupiter Life Line Hospitals Ltd. Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q2-2027)|% Change Since:8.52%|Next Earnings Date:Nov 09, 2023

Earnings Call SentimentPositive

The call was broadly constructive, supported by strong Q2 and H1 financial results, improving Dombivli EBITDA, a progressing expansion pipeline, solid mature-hospital occupancy, and a strong liquidity and leverage position. Counterbalancing factors included low Dombivli occupancy, ongoing hiring and insurance-empanelment work, Indore EBITDA fluctuations, capacity constraints at mature hospitals, and uncertainty around regulatory margin caps and formal financial guidance. Highlights significantly outweighed the lowlights.

Positive Updates

Pune South Land Acquisition Approved

The Board approved acquisition of the 11,452 sq m land leased for Pune South Hospital for INR 150 crores. The INR 50 crores deposit already paid will be adjusted, limiting incremental cash outflow to INR 100 crores. Registration was expected in the coming few days, and the Pune South project remains on schedule.

Negative Updates

Dombivli Occupancy Remains in the Mid-30s

Dombivli occupancy was currently in the mid-30s. Management said Q3 occupancies are traditionally lower than Q2 across its units, so some moderation should be expected, although the effect relative to ongoing growth remains to be seen.

Company Guidance

Management expects Pune South land to be registered in the coming few days, Mira-Bhayandar’s next phase to commence before the end of this financial year, and BKC to soon enter regulatory clearance; Dombivli’s broad budgetary model remains EBITDA breakeven in two years, with doctor hiring ongoing for the next year and a half, transplants starting in the next couple of quarters, and radiation oncology starting in the next quarter. Indore beds are not expected to be added in six months or for the next couple of quarters, with the target of reaching mid-60s occupancy first. Insurance typically takes about a year, empanelments around a year, and Dombivli fixed costs were INR 6 crore-INR 8 crore. The self-imposed debt ceiling is 3x of EBITDA; EBITDA to net cash has averaged around 70%, potentially tempered to some 60% something if net debt levels rise; maintenance CapEx is about INR 10 crores-INR 20 crores per unit, averaged over the next four or five years. For a new hospital, occupancy should go up and ARPOB rise faster than inflation over the first three years, while no financial guidance has been provided.

Jupiter Life Line Hospitals Ltd. Financial Statement Overview

Summary

Strong multi-year revenue growth and a clear profitability turnaround support the score, alongside a materially improved leverage profile and solid ROE in recent years. The key drag is cash-flow quality: free cash flow was sharply negative in 2025–2026 despite positive operating cash flow, indicating heavy reinvestment and/or working-capital absorption. A 2026 step-up in debt and margin compression versus 2025 add near-term monitoring risk.

Income Statement

78Positive

Balance Sheet

72Positive

Cash Flow

56Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	15.58B	15.00B	12.62B	10.70B	8.93B	7.33B
Gross Profit	9.84B	8.69B	10.31B	8.55B	7.11B	4.07B
EBITDA	3.69B	3.43B	3.25B	2.61B	2.06B	1.50B
Net Income	1.88B	1.94B	1.93B	1.77B	729.05M	511.28M
Balance Sheet
Total Assets	0	23.83B	19.05B	12.81B	9.86B	9.09B
Cash, Cash Equivalents and Short-Term Investments	5.40B	5.44B	6.03B	3.18B	1.36B	1.06B
Total Debt	0	5.84B	3.93B	623.41M	4.69B	4.95B
Total Liabilities	-15.44B	8.39B	5.49B	1.13B	6.22B	6.20B
Stockholders Equity	15.44B	15.44B	13.56B	11.69B	3.66B	2.94B
Cash Flow
Free Cash Flow	-403.95M	-2.34B	-674.22M	292.26M	399.24M	452.40M
Operating Cash Flow	1.30B	2.68B	2.53B	1.15B	1.17B	1.37B
Investing Cash Flow	-1.73B	-4.65B	-2.09B	-758.89M	-1.04B	-852.46M
Financing Cash Flow	-231.75M	1.60B	3.01B	1.28B	175.00M	322.02M

Jupiter Life Line Hospitals Ltd. Technical Analysis

Technical Analysis SentimentNeutral

Last Price263.60

Price Trends

50DMA271.64Negative

100DMA284.97Negative

200DMA270.46Negative

Market Momentum

MACD-4.21Negative

RSI48.75Neutral

STOCH42.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JLHL, the sentiment is Neutral. The current price of 263.60 is above the 20-day moving average (MA) of 250.36, below the 50-day MA of 271.64, and below the 200-day MA of 270.46, indicating a neutral trend. The MACD of -4.21 indicates Negative momentum. The RSI at 48.75 is Neutral, neither overbought nor oversold. The STOCH value of 42.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:JLHL.

Jupiter Life Line Hospitals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:JLHL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:YATHARTH	77Outperform	INR 89.42B	49.30	―	0.05%	44.00%	24.10%
IN:ARTEMISMED	73Outperform	INR 46.26B	38.38	―	0.15%	14.96%	20.76%
IN:INDRAMEDCO	72Outperform	INR 27.97B	14.90	―	1.31%	10.92%	12.12%
IN:HCG	69Neutral	INR 87.31B	375.35	―	―	13.65%	-40.97%
IN:JLHL	59Neutral	INR 84.02B	45.27	―	0.08%	16.71%	-6.09%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:SHALBY	35Underperform	INR 13.06B	34.08	―	―	6.50%	―

* General Sector Average

Performance Comparison

IN:JLHL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:JLHL	Jupiter Life Line Hospitals Ltd.	256.30	-57.49	-18.32%
IN:ARTEMISMED	Artemis Medicare Services Ltd.	292.20	47.66	19.49%
IN:HCG	HealthCare Global Enterprises Ltd.	584.80	-162.98	-21.79%
IN:INDRAMEDCO	Indraprastha Medical Corporation Limited	305.15	-263.62	-46.35%
IN:SHALBY	Shalby Ltd.	120.90	-123.30	-50.49%
IN:YATHARTH	Yatharth Hospital and Trauma Care Services Limited	928.05	114.33	14.05%

Jupiter Life Line Hospitals Ltd. Corporate Events

Jupiter Life Line Hospitals Publishes Unaudited Half-Year Financial Results

Oct 25, 2026

Jupiter Life Line Hospitals Ltd. has announced that its Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 at a meeting held on October 23, 2026. In line with...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 26, 2026

Jupiter Life Line Hospitals Ltd. AI Stock Analysis